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In neurons, mitochondria are enriched to provide energy and calcium buffering required for synaptic transmission.
Additionally, mitochondria localize to the synapse, where they are critical for the mobilization of reserve pool
vesicles and for neurotransmitter release. Previously, functional defects in mitochondria were considered to be
downstream effects of neurodegenerative diseases. However, more recent findings suggest mitochondria may serve
as key mediators in the onset and progression of some types of neurodegeneration. In this review, we explore the
possible roles of altered mitochondrial function and dynamics in the pathogenesis of neurodegenerative disorders,
with a particular focus on Alzheimer’s disease (AD) and Parkinson’s disease (PD), which have highlighted the
important role of mitochondria in neurodegeneration. While inheritable diseases like Charcot-Marie-Tooth disease
type 2A are concretely linked to gene mutations affecting mitochondrial function, the cause of mitochondrial
dysfunction in primarily sporadic diseases such as AD and PD is less clear. Neuronal death in PD is associated with
defects in mitochondrial function and dynamics arising from mutations in proteins affecting these processes,
including α-synuclein, DJ-1, LRRK2, Parkin and Pink1. In the case of AD, however, the connection between
mitochondria and the onset of neurodegeneration has been less clear. Recent findings, however, have implicated
altered function of ER-mitochondria contact sites and amyloid beta- and/or tau-induced defects in mitochondrial
function and dynamics in the pathogenesis of AD, suggesting that mitochondrial defects may act as key mediators
in the pathogenesis of AD as well. With recent findings at hand, it may be postulated that defects in mitochondrial
processes comprise key events in the onset of neurodegeneration.
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In addition to providing the large amount of energy
required for synaptic communication in the form of
adenosine triphosphate (ATP), mitochondria also partici-
pate in a wide variety of other neuronal processes in-
cluding calcium buffering, intracellular signaling, lipid
flux, and mediate contact sites between mitochondria
and the endoplasmic reticulum (ER). New findings have
complicated our view of the mitochondrion by the elu-
cidation of new roles for mitochondria in cellular phy-
siology, which extend far beyond the traditional role
of ATP synthesis. The growing number of of identified
processes in which mitochondria play a role has also ledCorrespondence: j.mcinnes@jacobs-university.de
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reproduction in any medium, provided the orto new connections between mitochondrial dysfunction
and various pathologies in humans [1].
A variety of factors contribute to mitochondrial health
and fitness. Human mitochondrial DNA (mtDNA) en-
codes 13 proteins, which are essential for the assembly
and function of the mitochondrial respiratory comple-
xes. Given the small size of the mtDNA molecule, and
its high susceptibility to mutations due to close pro-
ximity to reactive oxygen species (ROS, a byproduct of
respiration), mtDNA maintenance and repair mecha-
nisms are critical for maintaining mitochondrial function
[2]. In neurons, defects in mtDNA damage repair lead to
the accumulation of deleterious mutations, resulting in
decreased mitochondrial respiratory activity and event-
ually neuronal death [3]. In addition to mtDNA, the
nuclear DNA (nDNA) encodes over 1000 mitochondrialThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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functional processes. Therefore, nDNA maintenance and
repair mechanisms in the nucleus also play an important
role in maintaining mitochondrial fitness, as the muta-
tion of nDNA genes encoding mitochondrial proteins
can lead to pathology [4].
An important factor contributing to mitochondrial
health is the dynamic balance of fission and fusion. Since
mitochondria cannot be synthesized de novo, the biogen-
esis of new mitochondria must begin from existing mito-
chondria. Mitochondrial fission is the process whereby
one mitochondrion physically separates into two inde-
pendent mitochondrial objects. To carry out fission, the
mitochondrial-localized Mff protein recruits the cyto-
solic dynamin-related Drp1 to the mitochondrial outer
membrane [5]. Once recruited to the membrane, Drp1
provides the mechanical force to pinch the membrane to
cause fission [6]. Fission is not only important for
increasing the number of mitochondria within a cell, but
also for the disposal of debris by mitophagy-mediated
pathways, and is therefore essential for maintaining mi-
tochondrial fitness [7,8]. Mitochondrial stress induces
fission, and since mitochondrial dysfunction is concomi-
tant with neuronal death, mitochondrial fragmentation
due to excessive fission is a hallmark of some neurode-
generative diseases [9]. Moreover, it has been shown that
normal levels of mitochondrial fission are required for
the mobilization of synaptic vesicles from reserve pools
for release into the synaptic cleft, and neurons deficient
in Drp1 fail to maintain normal neurotransmission fol-
lowing stimulation [10].
The opposite process of mitochondrial fission is
fusion, whereby two mitochondria physically combine to
become one single mitochondrion with a continuous
membrane. The GTPases Mfn1, Mfn2 and OPA1 are re-
quired for mitochondrial fusion, whereby the mitofusins
Mfn1 and Mfn2 facilitate outer membrane fusion and
OPA1 facilitates inner membrane fusion [11]. Mitochon-
dria are constantly undergoing fusion and fission at
various time points throughout their lifecycle, and this
dynamic balance gives rise to the diverse mitochondrial
morphology observed in cells [12]. A damaged mito-
chondrion may be rescued by its fusion with a healthy
mitochondrion, thereby promoting health and func-
tion of the mitochondrial population to ensure cellu-
lar fitness [13].
Recent years of research have elucidated the role of
interactions between the ER and mitochondria. ER-
mitochondrial interactions and contact sites are impor-
tant for processes including lipid modification and flux
[14,15], calcium buffering [16], mitochondrial fission
[17,18], and organelle inheritance [19,20]. In neurons,
ER-mitochondria contact sites are particularly important
as sites of calcium buffering, where ER and mitochondriacoordinate the release of large amounts of calcium ions
into the cytosol for intracellular signaling [21]. Notably, an
increased concentration of calcium ions in mitochondria
leads to an increase in respiratory complex activity and
ATP production, providing an important link between
intracellular signaling and mitochondrial respiration [22].
Importantly, ER-mitochondria contact sites mark sites of
mitochondrial fission, as they play a role in recruiting
Drp1 to Mff receptors, and also provide the initial mech-
anical force to constrict the membrane [17].
In neurodegeneration, mitochondrial dysfunction leads
to widespread disturbances in processes critical for neu-
ronal function, including coordinated calcium signaling
and neurotransmitter release at the synapse. Though re-
cent research has revealed more links between defects in
specific mitochondrial processes and the progression of
neurodegeneration, the exact executors (i.e. that which
mediates the onset of pathogenesis and neurodege-
neration) and pathomechanisms thereof remain poorly
defined. Nonetheless, growing evidence suggests mito-
chondria play a key role in the execution of neu-
rodegeneration, either due to defects in respiratory
function or by interaction with other organelles, such as
the ER or cytoskeleton. This review attempts to clarify
connections between defects in mitochondrial processes
and the execution of neurodegeneration, demonstrating
that mitochondria are now entering the spotlight for
investigating the pathological basis of neurodegenerative
diseases.
Parkinson’s disease
The hallmark characteristic of all adult-onset neurode-
generative disorders is the degeneration or death of neu-
rons. In can be broadly stated that this is due to a
breakdown in one or more cellular processes essential
for fitness, often involving the loss of quality control and
recycling mechanisms such as autophagy and the deg-
radation of aggregated or unfolded proteins. Parkinson’s
disease (PD) is a devastating neurodegenerative disorder
affecting about 4% of seniors over 80 years old, with an
average onset around age 60 [23]. While a small portion
of PD cases is inherited or due to other known genetic
factors, most cases of PD are sporadic. PD is characte-
rized by death of the dopaminergenic neurons (up to
70% by the time of death) in the substantia nigra region
of the brain. This resulting decrease in dopamine levels
leads to motor disorders such as limb tremors, stiffness,
slowness of movement, and postural instability. Addi-
tionally, there is no definitive test for the clinical diagno-
sis of PD and current treatment only aims to reduce the
severity of symptoms [24].
Initially, the most long-standing hypothesis consi-
dered the primary executor of neuronal death in PD to
be the formation of α-synuclein plaques, composed of
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bodies [25,26]. Though it was long believed that
α-synuclein was the primary executor of PD, mitochon-
dria were brought into the spotlight at the end of the
1990s when mutations in a protein named Parkin were
identified in a Japanese PD patient [27]. In coming years,
it would be described that Parkin is required for the deg-
radation of poorly functioning mitochondria by mi-
tophagy [7,28]. Soon after the discovery of Parkin
mutations linked to PD, another key player, the PTEN-
induced kinase 1 (Pink1), would be identified as mutated
in PD patients [29]. Today, it is known that Pink1 acts
upstream of Parkin, and that the interaction and/or
function of these two proteins is altered in PD patients,
commonly resulting from mutations in one or both
genes in familial cases of PD [30]. Moreover, recent
studies have found that α-synuclein itself can localize to
mitochondria and modulate their function by down-
regulating complex I activity in a dose-dependent man-
ner [31], and results in mitochondrial fragmentation
upon overexpression by promoting translocation of Drp1
to mitochondria [32].
The wealth of information gained from studying the
roles of Pink1 and Parkin in PD has given rise to new
hypotheses of how mitochondrial dysfunction may influ-
ence the pathogenesis of PD. Evidence suggests that in
healthy cells, the Pink1/Parkin pathway may act to con-
trol for and clear dysfunctional mitochondria, character-
ized by high ROS levels and low membrane potential
[13]. When a mitochondrion becomes dysfunctional,
Pink1 attaches to the outer mitochondrial membrane,
where it will recruit Parkin [33]. Upon recruitment of
Parkin, mitochondria become ubiquitinated, leading to
the induction of mitophagy [7]. Interestingly, the kinase
activity of Pink1 does not act on Parkin, suggesting that
there are other key mediators of mitochondrial function
and quality control, the elucidation of which will likely
prove fruitful in understanding and treating PD [34].
Moreover, major mitochondrial defects such as ele-
vated oxidative stress and a 20-30% decrease in the
activity of electron transport chain complexes are
characteristic of PD patients [35,36]. Taken together,
this data may suggest that in the case of PD, muta-
tions in Pink1 and/or Parkin prevent the clearance of
dysfunctional mitochondria; because mitochondrial
function is critical for providing energy to the cell as
well as for synaptic communication, this would ultim-
ately lead to neuronal death.
It is important to note, however, that experiments
investigating the role of Pink1/Parkin as possible media-
tors of mitochondrial function in PD have been limited
by their cellular models. Notably, investigations into the
possible functions of the Pink1/Parkin system in main-
taining cellular fitness have been limited to cultured cellstreated with the mitochondrial-uncoupling compound
carbonyl cyanide m-chlorophenylhydrazone (CCCP), and
there is currently little concrete evidence that the Pink1/
Parkin pathway is active in healthy cells. Therefore, how
mitochondrial fitness, the Pink1/Parkin pathway, and the
onset of neurodegeneration in PD relate to one another
in vivo remains to be concretely defined. Additionally,
experiments using different model organisms have con-
cluded with inconsistent results as to how mutations in
Pink1 and/or Parkin may influence mitochondrial dynam-
ics. In particular, while studies in Drosophila have shown
that Pink1 deficiency leads to swollen, perinuclear mito-
chondria [37,38], Pink1 deficiency in mammalian cells
leads to mitochondrial fragmentation [39,40]. Thus, the
exact mechanism how Pink1 influences mitochondrial
dynamics in humans remains undefined; nonetheless, it is
evident that Parkin and Pink1 play an important role in
regulating mitochondrial fission and fusion, and that this
may contribute to overall neuronal fitness.
In addition to α-synuclein, Parkin and Pink1, mutated
forms of the proteins DJ-1 and LRRK2, as are found in
specific forms of familial PD, have also recently been im-
plicated as modifiers of mitochondrial dynamics. Muta-
tions in the leucine-rich repeat kinase 2 (LRRK2) are
commonly found in both familial (autosomal-dominant)
and sporadic cases of PD. LRRK2 is a large multi-
domain protein kinase of unknown function, which
localizes to the cytosol and associates with the mito-
chondrial outer membrane [41]. Recent data has shown
that overexpression of wild-type LRRK2, as well as the
expression of mutated LRRK2 isoforms present in
autosomal-dominant PD patients, lead to mitochondrial
fragmentation by direct interaction with Drp1 [42].
Moreover, mutations in the DJ-1 protein, as found in
cases of autosomal-recessive PD, result in increased
Drp1 levels and increased mitochondrial fragmentation
[43]. Thus, altered mitochondrial dynamics, and in par-
ticular mitochondrial fragmentation, is a notable charac-
teristic in many forms of PD.
In summary, PD pathogenesis has been closely associ-
ated with defects in mitophagy and altered mitochon-
drial dynamics, and it is likely a combination of these
defects which leads to neuronal dysfunction during the
pathogenesis of PD. Current avenues of research are
focusing on the genetic factors affecting mitochondrial
function, as well as modifiers and possible rescue mech-
anisms thereof. Currently, efforts to develop therapies
for treating PD focus on either reducing protein plaques
or alleviating mitochondrial dysfunction, for example
by inducing expression of mitochondrial neuronal un-
coupling proteins [44] or bypassing respiratory complex
defects to restore normal ATP production. Further re-
search into the Pink1/Parkin pathway of mitophagy will
also likely be fruitful in identifying new proteins involved
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Alzheimer’s disease
Like Parkinson’s, Alzheimer’s disease (AD) is another de-
vastating neurodegenerative disorder, affecting an astoun-
ding ~6% of North Americans and Western Europeans
above the age of 60, and over 25% above the age of 85
[45]. The majority of AD cases are sporadic, though an
estimated 1-5% of patients carry genetic mutations that
are thought to contribute to the onset of AD. AD patients
present symptoms of dementia, including loss of long-
term memory, confusion, mood swings, and loss of lan-
guage skills [46]. In the case of AD, there are currently
multiple well-supported hypotheses as to its causes and
executors. The hallmark of AD is the death of neurons in
the cortex and hippocampus of the brain, and a single
executor of this neuronal death remains elusive [47].
Similar to PD, the formation of protein plaques is
characteristic of AD. One hypothesis holds that the ag-
gregation of amyloid β-peptide (Aβ) (involved in synap-
tic formation and repair) into plaques is the executor of
AD [48], which has also been genetically linked to famil-
ial AD cases in which mutations in the APP gene lead to
increased amounts of Aβ [49]. The APP gene encodes
the amyloid precursor protein (APP), which is processed
by α-, β- and/or γ-secretases to generate Aβ. In some
AD patients, one or more mutations near or within the
Aβ-encoding region of APP increase the affinity of APP
for β- and γ-secretase, thereby producing an estimated
six-fold increase in Aβ [50,51]. Additionally, some muta-
tions within the Aβ-encoding region also increase the
affinity of Aβ to self-aggregate into plaques, which are
neurotoxic [52]. Importantly, Aβ accumulates at mito-
chondria and inhibits respiratory complex IV, increasing
ROS production and thereby increasing the frequency of
mtDNA mutations [53]. Moreover, the studies of Wang
et al. have found that Aβ itself alters mitochondrial
dynamics by regulating the activities of proteins essential
for fission and fusion, such as Drp1, which can lead to
mitochondrial fragmentation [54-56]. These studies have
been further supported by findings that Aβ interacts
with Drp1, and that APP leads to widespread defects in
mitochondrial biogenesis, transport and synaptic activity
[57,58]. As discussed further below, altered mitochondrial
dynamics may comprise a key event in AD pathogenesis.
A second hypothesis has become popular in recent
years, which holds that hyperphosphorylation of the
microtubule-stabilizing tau protein, sporadically or by
genetic mutation [59], leads to its aggregation and there-
fore the formation of neurofibrillary tangles which act as
executors of AD [60,61]. Tau is a microtubule-associated
protein, which binds microtubules in an unphosphory-
lated state and stabilizes them. When mutations in thetau-encoding MAPT gene lead to hyperphosphorylation
of tau, there is a two-fold effect. First, hyperphospho-
rylated tau is more likely to aggregate and form neu-
rotoxic protein plaques, and does so in tauopathies.
Second, decreased tau binding to microtubules decreases
their stability. Mitochondria are transported to the syn-
apse along the axon on linear microtubules by the action
of a kinesin KIF5 motor protein [62], where they are
critical for synaptic transmission [63]. Thus, the des-
tabilization of microtubules is likely to affect mitochon-
drial transport to the axon, and thereby impair synaptic
communication.
In the case of PD, recent findings have directly linked
some PD-associated mutated genes with defects in mito-
chondrial function and/or dynamics. However, as muta-
tions in genes relevant to AD are primarily either in
genes encoding APP or tau, the role of mitochondria in
the pathogenesis of AD is less clear. Nonetheless, re-
search in the last year has renewed attention in the role
of mitochondria in the pathogenesis of AD with the
findings that mutations in APP and tau may have direct
affects on mitochondrial function and dynamics. As
mentioned above, the destabilization of microtubules by
mutations in MAPT is one way in which mitochondrial
transport and synaptic transmission are affected by tau
hyperphosphorylation. Most recently, one article reports
that overexpression of wild-type tau promotes neurodege-
neration in Drosophila by blocking mitochondrial loca-
lization of Drp1, leading to elongated and dysfunctional
mitochondria, and causing neurotoxicity [64]. Though
overexpression of wild-type tau is not directly associated
with AD pathogenesis, this provides important evidence
that tau itself may directly or indirectly influence mito-
chondrial dynamics both in healthy neurons as well as in
AD pathogenesis [65]. In another study, expression of the
Asp421-cleaved tau isoform, characteristic in the early
stages of AD pathogenesis, has been found to lead to
mitochondrial fragmentation in rat neurons [66]. More-
over, another article reported that in SY5Y cells, hyper-
phosphorylated mutant tau decreases respiratory complex
I activity, decreases rates of fission and fusion, and makes
cells more vulnerable to oxidative stress [67]. Taken to-
gether, these findings suggest that MAPT mutations may
directly affect mitochondrial function and dynamics, and
thereby may constitute a key event in AD pathogenesis by
causing a deficit in respiratory complex activity, and by
leading to mitochondrial fragmentation, both of which are
characteristic of the breakdown of neuronal fitness and
activity.
As described above, ER-mitochondria contact sites are
critical for maintaining mitochondrial function as well as
a diverse range of other cellular activities. Recently, it
was discovered that ER-mitochondria contact sites are
enriched in the presenilins PS1 and PS2 [68]. Presenilins
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the γ-secretase complex for the proteolytic processing of
APP to Aβ [69]. Mutations in PS1- and PS2-encoding
genes have been associated with the overproduction of
Aβ by γ-secretase and lead to familial AD [70,71]. Inter-
estingly, γ-secretase activity at ER-mitochondria contact
sites was found to be approximately five-fold higher than
in the ER or mitochondria alone, and thus ER-mitochon-
dria contacts are primary sites of Aβ production [68].
Moreover, new evidence shows that ER-mitochondrial
contact sites exhibit increased activity and communication
under conditions of AD, resulting in altered calcium
signaling and lipid metabolism in affected cells [72]. These
data support a new hypothesis in which mutations in
genes encoding APP, PS1 and/or PS2 increase Aβ produc-
tion by γ-secretase at ER-mitochondria contact sites, and
thereby alter ER and mitochondrial function as the first
step in pathogenesis. As mentioned above, Aβ accumu-
lates in mitochondria, where it induces mtDNA mutations
and causes decreased respiratory complex activity [53].
Therefore, under this hypothesis, mutations that lead to
increased Aβ production would first impair mitochondrial
function, thereby affecting cellular calcium and lipid
homeostasis, which may have downstream effects leading
to increased Aβ and tau aggregation, and ultimately neur-
onal death [73]. In this scenario, AD-associated mutations
directly impair the function of mitochondria and ER-
mitochondria contact sites leading to downstream effects
characteristic of AD, thus establishing mitochondria as
executors of AD pathogenesis.
Other neurodegenerative diseases
Since the majority of PD and AD cases are sporadic and
not inherited, elucidating the role of mitochondria in
neurodegeneration has proved difficult from a genetic
standpoint. In some cases, it is difficult to identify if al-
terations in mitochondrial function are causes of neuro-
degeneration, or downstream effects of other primary
executors. However, in other inheritable neurodegenera-
tive diseases the role of mitochondria as executors of
neurodegeneration is more clear, particularly those in
which mutations directly affect mitochondrial proteins.
Charcot-Marie-Tooth disease (CMTD) type 2A is an
early-onset neurodegenerative disorder, in which mito-
chondrial dysfunction arising from a nDNA mutation
encoding a mitochondrial protein is the primary execu-
tor in the onset of neuronal death. CMTD patients carry
heterozygous mutations in the gene encoding Mfn2,
required for mitochondrial outer membrane fusion [74].
The result is the inhibition of fusion, leading to mito-
chondrial fragmentation and dysfunction [9]. Moreover,
it was recently identified that Mfn2 mutations in CMTD
also lead to mtDNA depletion, leading to respiratory
complex deficiencies and metabolic dysfunction [75].Together, this combination of excessive mitochondrial
fragmentation and mtDNA depletion lead to severe
mitochondrial dysfunction and ultimately the death of
peripheral nerves.
Mitochondrial dysfunction associated with inheritable
nDNA or mtDNA mutations, which affect mitochondrial
function either directly or indirectly, has been implicated
in a number of neurodegenerative diseases. Examples in-
clude amyotrophic lateral sclerosis, Huntington’s disease,
optic atrophy, and spinocerebellar ataxia, the causes of
which have been discussed elsewhere [76]. Most re-
cently, mitochondrial dysfunction has been associated
with the onset of autism spectrum disorder, providing
yet another link between mitochondria and neurolo-
gical disorders [77].Conclusion
Altered mitochondrial function and dynamics are hall-
mark characteristics of neuronal death. However, whether
this dysfunction is a downstream effect of neuropatho-
genesis, or a key mediator thereof, remains unclear. In the
case of PD and CMTD, inheritable disease-associated
mutations can directly affect mitochondrial proteins asso-
ciated with mitochondrial function and dynamics, and
therefore provide a more clear genetic linkage between
mitochondrial defects and neurodegeneration. In the case
of AD, however, the role of mitochondria has been less
clear, as mutations carried by AD patients do not directly
affect mitochondrial proteins. However, recent findings
suggest that mitochondrial dysfunction may precede
plaque formation in its pathogenesis, and have implicated
Aβ, APP and tau as mediators of mitochondrial function
and dynamics, thereby suggesting a link between mi-
tochondrial deficiencies and AD-associated mutations.
Taking recent findings into account, alterations in mito-
chondrial function and dynamics may act as pathomecha-
nisms in neurodegeneration. Therefore, future research
should focus on rescuing mitochondrial functional defects,
such as respiratory complex activity, as well as restoring
the balance of mitochondrial fission and fusion as poten-
tial therapeutic targets for neurodegenerative disorders.
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